| Shockwave Medical Reports First Quarter 2024 Financial ResultsGlobeNewswireMay 06, 2024 SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to working together to bring our life-changing therapies to even more patients across the globe." First Quarter 2024 Financial Results Revenue for the first quarter ended March 31, 2024, was $218.8 million, a 36% increase from $161.1 million in the same period of 2023. The growth in revenue was primarily driven by increased adoption of Shockwave products in both the United States and internationally. Gross profit for the first quarter of 2024 was $190.6 million compared to $140.0 million for the first quarter of 2023. Gross margin percentage was 87% for the three months ended March 31, 2024, consistent with gross margin for the three months ended March 31, 2023. Total operating expenses for the first quarter of 2024 were $148.2 million, a 48% increase from $100.2 million in the first quarter of 2023. The increase was primarily driven by sales force expansion and higher headcount to support the growth of the business. Net income for the first quarter of 2024 was $55.3 million, compared to net income of $39.1 million in the same period of 2023. Basic and diluted net income per share for the first quarter of 2024 was $1.48 and $1.44, respectively. Adjusted EBITDA improved by approximately 19% to $68.5 million, in the first quarter of 2024, compared to adjusted EBITDA of $57.5 million in the first quarter of 2023. Adjusted EBITDA is a non-GAAP measure. Cash, cash equivalents and short-term investments totaled $1,029.2 million as of March 31, 2024. 2024 Financial Guidance Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical is withdrawing its full year 2024 guidance, previously issued on February 15, 2024. Conference Call Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical will not be hosting the previously scheduled earnings conference call today. About Shockwave Medical, Inc. Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave Medical has also recently acquired the Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com. Forward-Looking Statements This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," and similar expressions, and the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding our pending acquisition by Johnson & Johnson, our business strategy and plans, our objectives for future operations and financial performance and other matters. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the pending acquisition will not be satisfied, including the risk that clearance under the Hart-Scott-Rodino Antitrust Improvements Act or other applicable antitrust laws will not be obtained; uncertainty as to the percentage of our stockholders that will vote to approve the proposed transaction; the possibility that the transaction will not be completed in the expected timeframe or at all; potential adverse effects to our business or the business of Johnson & Johnson during the pendency of the transaction, such as employee departures or distraction of management from business operations; the risk of stockholder litigation relating to the transaction, including resulting expense or delay; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in the sections titled "Risk Factors" in our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in our other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations. Use of Non-GAAP Financial Measures This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP), including references to adjusted EBITDA, a non-GAAP financial measure that excludes from net income the effects of income tax (benefit) provision, other (expense) income, net, interest expense, interest income, income (loss) from equity method investment, depreciation and amortization, and stock-based compensation. We believe the presentation of adjusted EBITDA is useful as it provides visibility to our underlying continuing operating performance by excluding the impact of certain items that are non-cash in nature or not related to our core business operations. Our definition of adjusted EBITDA may differ from similarly titled measures used by others. Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease our reported results of operations, management strongly encourages investors to review, when they become available, our consolidated financial statements and publicly filed reports in their entirety. A reconciliation of adjusted EBITDA to net income has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation. Media Contact: Scott Shadiow+1.317.432.9210sshadiow@shockwavemedical.com Investor Contact:Debbie Kasterdkaster@shockwavemedical.com SHOCKWAVE MEDICAL, INC.Balance Sheet Data(in thousands)March 31,2024December 31,2023(Unaudited)ASSETSCURRENT ASSETS:Cash and cash equivalents$281,674$328,422Short-term investments747,559662,132Accounts receivable, net124,440114,552Inventory111,215107,587Prepaid expenses and other current assets10,46212,567Total current assets1,275,3501,225,260Operating lease right-of-use assets34,91929,707Property and equipment, net78,69368,923Equity method investment2,3561,643Intangible assets, net91,96092,857Goodwill39,56839,568Deferred tax assets111,90099,169Other assets9,0019,436TOTAL ASSETS$1,643,747$1,566,563LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES:Accounts payable$9,843$8,868Accrued liabilities78,83891,696Lease liability, current portion3,6533,641Total current liabilities92,334104,205Lease liability, noncurrent portion40,33635,103Convertible debt, noncurrent portion732,810731,863Related party contract liability, noncurrent portion12,27312,273Deferred tax liabilities3,6093,609Long-term income tax liability2,9691,526Other liabilities7,6599,307TOTAL LIABILITIES891,990897,886STOCKHOLDERS' EQUITY:Common stock3837Additional paid-in capital586,017557,882Accumulated other comprehensive (loss) income(109)293Retained earnings165,811110,465TOTAL STOCKHOLDERS' EQUITY751,757668,677TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$1,643,747$1,566,563SHOCKWAVE MEDICAL, INC. Statement of Operations Data(Unaudited)(in thousands, except share and per share data) Three Months EndedMarch 31,20242023Revenue:Product revenue$218,805$161,066Cost of revenue:Cost of product revenue28,20721,066Gross profit190,598140,000Operating expenses:Research and development44,46626,971Sales and marketing74,49254,011General and administrative29,23319,204Total operating expenses148,191100,186Income from operations42,40739,814Income (loss) from equity method investment713(823)Interest income12,3181,740Interest expense(2,943)(636)Other (expense) income, net(2,496)642Net income before taxes49,99940,737Income tax (benefit) provision(5,347)1,612Net income$55,346$39,125Net income per share, basic$1.48$1.07Net income per share, diluted$1.44$1.03Shares used in computing net income per share, basic37,284,94636,427,263Shares used in computing net income per share, diluted38,472,01337,979,448SHOCKWAVE MEDICAL, INC.Reconciliation of GAAP Net Income to Adjusted EBITDA(Unaudited)(in thousands)Three Months EndedMarch 31,20242023GAAP Net Income$55,346$39,125Non-GAAP AdjustmentsIncome tax (benefit) provision(5,347)1,612Other expense (income), net2,496(642)Interest expense2,943636Interest income(12,318)(1,740)(Income) loss from equity method investment(713)823Depreciation and amortization3,1091,708Stock-based compensation expense22,93715,967Adjusted EBITDA$68,453$57,489COMTEX_451974690/2010/2024-05-06T16:05:33 SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to working together to bring our life-changing therapies to even more patients across the globe." First Quarter 2024 Financial Results Revenue for the first quarter ended March 31, 2024, was $218.8 million, a 36% increase from $161.1 million in the same period of 2023. The growth in revenue was primarily driven by increased adoption of Shockwave products in both the United States and internationally. Gross profit for the first quarter of 2024 was $190.6 million compared to $140.0 million for the first quarter of 2023. Gross margin percentage was 87% for the three months ended March 31, 2024, consistent with gross margin for the three months ended March 31, 2023. Total operating expenses for the first quarter of 2024 were $148.2 million, a 48% increase from $100.2 million in the first quarter of 2023. The increase was primarily driven by sales force expansion and higher headcount to support the growth of the business. Net income for the first quarter of 2024 was $55.3 million, compared to net income of $39.1 million in the same period of 2023. Basic and diluted net income per share for the first quarter of 2024 was $1.48 and $1.44, respectively. Adjusted EBITDA improved by approximately 19% to $68.5 million, in the first quarter of 2024, compared to adjusted EBITDA of $57.5 million in the first quarter of 2023. Adjusted EBITDA is a non-GAAP measure. Cash, cash equivalents and short-term investments totaled $1,029.2 million as of March 31, 2024. 2024 Financial Guidance Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical is withdrawing its full year 2024 guidance, previously issued on February 15, 2024. Conference Call Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical will not be hosting the previously scheduled earnings conference call today. About Shockwave Medical, Inc. Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave Medical has also recently acquired the Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com. Forward-Looking Statements This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," and similar expressions, and the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding our pending acquisition by Johnson & Johnson, our business strategy and plans, our objectives for future operations and financial performance and other matters. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the pending acquisition will not be satisfied, including the risk that clearance under the Hart-Scott-Rodino Antitrust Improvements Act or other applicable antitrust laws will not be obtained; uncertainty as to the percentage of our stockholders that will vote to approve the proposed transaction; the possibility that the transaction will not be completed in the expected timeframe or at all; potential adverse effects to our business or the business of Johnson & Johnson during the pendency of the transaction, such as employee departures or distraction of management from business operations; the risk of stockholder litigation relating to the transaction, including resulting expense or delay; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in the sections titled "Risk Factors" in our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in our other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations. Use of Non-GAAP Financial Measures This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP), including references to adjusted EBITDA, a non-GAAP financial measure that excludes from net income the effects of income tax (benefit) provision, other (expense) income, net, interest expense, interest income, income (loss) from equity method investment, depreciation and amortization, and stock-based compensation. We believe the presentation of adjusted EBITDA is useful as it provides visibility to our underlying continuing operating performance by excluding the impact of certain items that are non-cash in nature or not related to our core business operations. Our definition of adjusted EBITDA may differ from similarly titled measures used by others. Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease our reported results of operations, management strongly encourages investors to review, when they become available, our consolidated financial statements and publicly filed reports in their entirety. A reconciliation of adjusted EBITDA to net income has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation. Media Contact: Scott Shadiow+1.317.432.9210sshadiow@shockwavemedical.com Investor Contact:Debbie Kasterdkaster@shockwavemedical.com SHOCKWAVE MEDICAL, INC.Balance Sheet Data(in thousands)March 31,2024December 31,2023(Unaudited)ASSETSCURRENT ASSETS:Cash and cash equivalents$281,674$328,422Short-term investments747,559662,132Accounts receivable, net124,440114,552Inventory111,215107,587Prepaid expenses and other current assets10,46212,567Total current assets1,275,3501,225,260Operating lease right-of-use assets34,91929,707Property and equipment, net78,69368,923Equity method investment2,3561,643Intangible assets, net91,96092,857Goodwill39,56839,568Deferred tax assets111,90099,169Other assets9,0019,436TOTAL ASSETS$1,643,747$1,566,563LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES:Accounts payable$9,843$8,868Accrued liabilities78,83891,696Lease liability, current portion3,6533,641Total current liabilities92,334104,205Lease liability, noncurrent portion40,33635,103Convertible debt, noncurrent portion732,810731,863Related party contract liability, noncurrent portion12,27312,273Deferred tax liabilities3,6093,609Long-term income tax liability2,9691,526Other liabilities7,6599,307TOTAL LIABILITIES891,990897,886STOCKHOLDERS' EQUITY:Common stock3837Additional paid-in capital586,017557,882Accumulated other comprehensive (loss) income(109)293Retained earnings165,811110,465TOTAL STOCKHOLDERS' EQUITY751,757668,677TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$1,643,747$1,566,563SHOCKWAVE MEDICAL, INC. Statement of Operations Data(Unaudited)(in thousands, except share and per share data) Three Months EndedMarch 31,20242023Revenue:Product revenue$218,805$161,066Cost of revenue:Cost of product revenue28,20721,066Gross profit190,598140,000Operating expenses:Research and development44,46626,971Sales and marketing74,49254,011General and administrative29,23319,204Total operating expenses148,191100,186Income from operations42,40739,814Income (loss) from equity method investment713(823)Interest income12,3181,740Interest expense(2,943)(636)Other (expense) income, net(2,496)642Net income before taxes49,99940,737Income tax (benefit) provision(5,347)1,612Net income$55,346$39,125Net income per share, basic$1.48$1.07Net income per share, diluted$1.44$1.03Shares used in computing net income per share, basic37,284,94636,427,263Shares used in computing net income per share, diluted38,472,01337,979,448SHOCKWAVE MEDICAL, INC.Reconciliation of GAAP Net Income to Adjusted EBITDA(Unaudited)(in thousands)Three Months EndedMarch 31,20242023GAAP Net Income$55,346$39,125Non-GAAP AdjustmentsIncome tax (benefit) provision(5,347)1,612Other expense (income), net2,496(642)Interest expense2,943636Interest income(12,318)(1,740)(Income) loss from equity method investment(713)823Depreciation and amortization3,1091,708Stock-based compensation expense22,93715,967Adjusted EBITDA$68,453$57,489COMTEX_451974690/2010/2024-05-06T16:05:33 |
0.23% $0.36
